The impact of the oncological treatment on the quality of life of elderly with breast cancer assisted by the brazilian Public Health System

• Autor(a) principal: Moehlecke, Bárbara Zanesco
• Data de Publicação: 2022
• Outros Autores: Melo, Renan Oliveira de, Renck, Daiana, Aumann, Victoria, Kunde, Mathias André, Cappellari, Angélica Regina, Engroff, Paula, Morrone, Fernanda Bueno
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: PAJAR - Pan American Journal of Aging Research
• Texto Completo: https://revistaseletronicas.pucrs.br/ojs/index.php/pajar/article/view/43014
• topic: aged; breast câncer; quality of life; medication adherence; drug interactions; anciano; cáncer de mama; calidad de vida; cumplimiento de la medicación; interacciones farmacológicas; idoso; neoplasias da mama; qualidade de vida; adesão à medicação; interações medicamentosas

Aims: to evaluate the quality of life (QV), drug interactions and adherence to treatment in elderly patients with breast cancer who did cancer treatment through the brazilian Public Health System (SUS).Methods: prospective cohort, with six months of follow-up, which included elderly patients with breast cancer treated at the University Hospital of Porto Alegre and assisted by the SUS. Women aged ≥ 60 years were selected, divided into two groups (60-69 years and ≥ 70 years).Results: thirty-eight patients were included in the QV and treatment adherence analysis. Within the molecular classification, the most diagnosed subtypes were Luminal B/Her2- (34,2%), Luminal A (26,3%), Luminal B/HER2+ (21,1%). Physical symptoms most related to the disease, at the time of the diagnosis, were insomnia, musculoskeletal stiffness, concerns regarding other people and the future. In contrast, six months later the less favorable results were fatigue, nausea and vomit, dyspnea, pain, inappetence, constipation, diarrhea, financial issues, systemic treatment adverse events, symptoms in the breasts and arms, and alopecia. Low treatment adherence was identified in 67.6% of patients. Polypharmacy was evidenced in 60.6%, and at least one potential drug interaction was observed in 78.8% of the sample. The average of medicines used was 7.24 (SD= 3.77). Conclusions: this study demonstrated the importance of monitoring the elderly population with breast cancer that uses chemotherapy, in order to understand the implications of senescence, as well as improve the rates of adherence to therapy and the quality of life of this population.